Scynexis vs Spero Therapeutics
SCYX and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SCYX and SPRO compare
Spero Therapeutics is the larger company, worth 1.9 times as much as Scynexis ($55.1M against $29.0M).
Scynexis grew revenue faster over the last twelve months (490% versus −3.3% for Spero Therapeutics).
Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −53.3% at Scynexis.
Scynexis scores higher on the StockData Score (13 against 11 for Spero Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SCYX | SPRO |
|---|---|---|
| Size and price | ||
| Market cap | $29.0M | $55.1M |
| Share price | $2.91 | $0.946 |
| Change, 1 year | −38.4% | −61.2% |
| Change, 5 years | −95.1% | −93.7% |
| Beta (5Y) | 1.56 | 1.28 |
| Employees | 18 | 25 |
| StockData Score | ||
| Total score | 13 (better) | 11 |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 0 |
| Performance score | 3 | 3 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 23.7× |
| P/S | 1.5× | 1.2× (better) |
| P/B | 0.4× (better) | 1.2× |
| EV/EBITDA | – | 0.7× |
| Fair value | $10.10 | $1.64 |
| Margin of safety | 71.2% (better) | 42.4% |
| Growth | ||
| Revenue growth (TTM) | 490% (better) | −3.3% |
| Revenue growth, 5Y average | – | 48.2% |
| Profitability | ||
| Operating margin | −118% | 12.8% (better) |
| Net margin | −53.3% | 15.7% (better) |
| Return on equity | −18.4% | 19.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.65 (better) | 6.12 |
| Altman Z-score | −5.22 (better) | −6.30 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 51.7% | 36.9% |
| Held by insiders | 24.8% | 24.6% |
| Insider net buying, 12 months | – | −$499K |
| Short interest, % of float | 6.0% | 1.8% |
Go deeper
- SCYX stock overview
- SCYX income statement
- SCYX valuation and score
- SPRO stock overview
- SPRO income statement
- SPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.